# US 2010/0168074 A1 · Freezable Unit Dosage Delivery System and Method of Preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168074 A1
- Document ID: US20100168074A1
- Status: Published application
- Kind: A1
- Application number: 12/595,808
- Filed: 2008-04-11
- Published: 2010-07-01
- Earliest claimed: 2007-04-13
- Assignees: Christopher Culligan
- Inventors: Christopher Culligan; Neil Smith; Rob Hart; Jay Sankey
- Web page: https://patentgrep.com/patent/US20100168074A1

## CPC

- A61K 9/2095: {Tabletting processes}
- A61J 1/03: for pills or tablets (containers for pills or tablets with special dispensing means therefor B65D83/04)
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- B65D 75/327: {and forming several compartments}
- B65D 2575/3245: by peeling off the non-rigid sheet
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- B65D: CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES

## Abstract

A freezable unit dosage delivery system, method of preparation, a solid unit dosage, method of treating symptoms and conditions, and kit is disclosed. The freezable unit dosage delivery system includes a composition, preferably containing one or more medicinal ingredients, having a freezing point less than 5° C.; a storage container comprising one or more cavity, each configured to receive a unit dosage quantity of the composition; and a sealing sheet for sealing engagement with the storage container. Upon freezing, the unit dosage quantity solidifies into a solid unit dosage that may be administered one of orally, rectally or vaginally for the local or systemic treatment of symptoms and conditions in a human.

## Claims

### Claim 1

A freezable unit dosage delivery system comprising:
(a) a composition comprising at least one active ingredient and a physiologically or pharmaceutically acceptable carrier, said composition having a freezing point of 5° C. or less;
(b) a storage container comprising one or more liquid-impermeable cavities, each cavity configured to receive a unit dosage quantity of the composition; and
(c) a sealing sheet for sealing engagement with the storage container, the sealing sheet adapted to cooperate with at least one cavity to define a unit dosage of the composition and to form a leak resistant seal enclosing the at least one cavity suitable for containing the unit dosage quantity of the composition within the cavity;
wherein the unit dosage quantity solidifies into a solid unit dosage of the composition within each cavity upon freezing.

### Claim 2 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein unit dosage quantity is in liquid or flowable form at room temperature prior to freezing.

### Claim 3 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the unit dosage quantity is in liquid or flowable form at a temperature in the range of 10° C. to 35° C. prior to freezing.

### Claim 4 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the composition has a freezing point below 0° C.

### Claim 5 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the unit dosage quantity solidifies into a solid unit dosage form upon freezing at a temperature in the range of −20° C. to 5° C.

### Claim 6 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the solid unit dosage substantially conforms to the shape defined by the cavity.

### Claim 7 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the solid unit dosage is suitable for one of oral, rectal or vaginal administration, for locally or systemically treating symptoms or conditions of a human.

### Claim 8 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the solid unit dosage is in a configuration selected from the group consisting of lozenge, tablet, capsule, ring, star, geometric shapes, suppository, torpedo or candy confectionary.

### Claim 9 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the storage container and sealing sheet are in the form of a blister pack.

### Claim 10 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the sealing sheet is adapted to releasably sealing engage the storage container.

### Claim 11 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the sealing sheet and the storage container are further provided with sealing means adapted to sealingly engage the sealing sheet to the storage container on manual application.

### Claim 12 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the active ingredient is an herbal, pharmaceutical or nutritional ingredient.

### Claim 13 (depends on 12)

The freezable unit dosage delivery system of claim 12 wherein the active ingredient is selected from the group consisting of antibiotic agents, antifungal agents, antiinfective agents, antiviral agents, antiseptics, analgesics, decongestants, antihistamine, sedatives, anxiolytics, diuretics, stimulants, expectorants, muscle relaxants, antacids, anti-inflammatories, antipsycotics, antidepressants, neuroleptics, antipyretics, antitussives, steroids, chemotherapies, antiarrhythmics, diuretics, antinausea, hyperglycemics, antiepileptics, motility agents, and antihypertensives.

### Claim 14 (depends on 12)

The freezable unit dosage delivery system of claim 12 wherein the active ingredients selected from the group consisting of dextromethophan, guaifenesin, lidocaine/sylocalne, phenylephrine, codeine sulfate, benzydamine, aspirin, non-steroidal anti-inflammatory drugs such as arylalkanoic acids, 2-arylpropionic acids, N-arylanthranilic acids, pryrazolidine derivatives, oxicans, COX-2 inhibitors or sulphonanilides, acetominophen, ibuprofen and amoxicillin.

### Claim 15 (depends on 12)

The freezable unit dosage delivery system of claim 12 wherein the active ingredient is selected from the group consisting of garlic, arabinogalactan, St. John's wart, goldenseal, eyebright, licorice, rose hips, chamomile, slippery elm bark, echinacea, ginkgo biloba, red doer, sarsaparilla, uva ursi, aloe vera, black cohosh, green tea, cat's claw, devil's claw, buchu, ginseng, dandelion, raspberry leaf, spearmint, peppermint, comfrey, senna, feverfew, ginger, calendula, dong quai, cranberry, ephedra, hawthorn, juniper, thistle, valerian, elder tree, green coffee bean, green cacao bean, artichoke, birch tree, wild yam, agnus castus, passion flower, saw palmetto and schizandra.

### Claim 16 (depends on 12)

The freezable unit dosage delivery system of claim 12 wherein the active ingredient is selected from the group consisting of vitamin A, vitamin C, vitamin D, vitamin E, vitamin B1, vitamin B6, vitamin B12, niacinamide, pantothenic acid, thiamin, riboflavin, paba, choline inositol folic acid, biotin, calcium, magnesium, iron, chromium, manganese, zinc, potassium, phosphorus, selenium and iodine.

### Claim 17 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the physiological or pharmaceutically acceptable carrier includes water, an alcohol, a polyol, a polyether polyol, a derivative of a polyether polyol, glycerol, gelatin, mineral oil, olive oil, corn oil or any other consumable biologic or synthetic oil.

### Claim 18 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the composition further includes one or more constituents selected from the group consisting of buffering agents, stabilizers, surfactants, preservatives, coloring agents, sweeteners, or flavouring agents.

### Claim 19 (depends on 1)

The freezable unit dosage delivery system of claim 1 wherein the sealing sheet is adapted for sealing engagement with the storage container by means selected from the group consisting of adhesive, heat sealing, lamination, or mechanical means, including lid means, frictional engagement means, tongue-in-groove means and interlocking means.

### Claim 20

A method for preparing a freezable unit dosage, comprising the steps of:
(a) providing a composition comprising at least one active ingredient and a physiologically or pharmaceutically acceptable carrier, said composition has a freezing point of about 5° C. or less;
(b) providing a storage container comprising one or more liquid-impermeable cavities, each cavity configured to receive a unit dosage quantity of the composition,
(c) placing a unit dosage quantity of the composition into at least one or more of the cavities; and
(d) applying a sealing sheet to sealing engage the storage container, the sealing sheet cooperating with at least one cavity to define a unit dosage of the composition and forming a leak resistant seal enclosing the unit dosage quantity of the composition within the cavity,
wherein the unit dosage quantity solidifies into a solid unit dosage of the composition within each cavity upon freezing.

### Claim 21 (depends on 20)

The method of claim 20 further providing instructions to subject the storage container containing the unit dosages to freezing.

### Claim 22 (depends on 21)

The method of claim 21 wherein freezing includes subjecting the storage container to a temperature of below 5° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 23 (depends on 21)

The method of claim 21 wherein freezing includes subjecting the storage container to a temperature of below 0° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 24 (depends on 21)

The method of claim 21 wherein freezing includes subjecting the storage container to a temperature in the range of −20° C. to 0° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 25 (depends on 21)

The method of claim 21 wherein unit dosage quantity is in liquid or flowable form at room temperature prior to freezing.

### Claim 26 (depends on 21)

The method of claim 21 wherein the unit dosage quantity is in liquid or flowable form at a temperature in the range of 10° C. to 35° C.

### Claim 27 (depends on 21)

The method of claim 21 wherein the composition has a freezing point below 0° C.

### Claim 28 (depends on 21)

The method of claim 21 wherein the unit dosage quantity solidifies into a solid unit dosage form upon freezing at a temperature in the range of −20° C. to 5° C.

### Claim 29 (depends on 21)

The method of claim 21 wherein the sealing sheet is manually applied to the storage container.

### Claim 30 (depends on 21)

The method of claim 21 wherein the sealing sheet is applied using an adhesive or mechanical means.

### Claim 31 (depends on 21)

The method of claim 21 wherein the active ingredient is an herbal, pharmaceutical or nutritional ingredient.

### Claim 32 (depends on 21)

The method of claim 21 wherein the physiological or pharmaceutically acceptable carrier includes water, an alcohol, a polyol, a polyether polyol, a derivative of a polyether polyol, glycerol, gelatin, mineral oil, olive oil, corn oil or any other consumable biologic or synthetic oil.

### Claim 33 (depends on 21)

The method of claim 21 wherein the one or more cavities of the storage container are selected so as to define a configuration for the solid unit dosage subsequent to freezing.

### Claim 34 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A solid unit dosage form prepared by the method according to any one of claims 20 to 33.

### Claim 35 (depends on 34)

The solid unit dosage form of claim 34, wherein the solid unit dosage form is adapted for one of oral, vaginal or rectal administration, for locally or systemically treating symptoms or conditions of a human.

### Claim 36 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

Use of a solid unit dosage form prepared by the method according to any one of claims 20 to 33 for locally or systemically treating symptoms or conditions of a human.

### Claim 37

A method for locally or systemically treating symptoms or conditions of a human in need of such treatment comprising the steps of:
(a) providing a solid unit dosage prepared by:
(i) providing a composition comprising at least one active ingredient and a physiologically or pharmaceutically acceptable carrier, said composition has a freezing point of about 5° C. or less;
(ii) providing a storage container comprising one or more liquid-impermeable cavities, each cavity configured to receive a unit dosage quantity of the composition,
(iii) placing a unit dosage quantity of the composition into at least one or more of the cavities; and
(iv) applying a sealing sheet to sealing engage the storage container, the sealing sheet cooperating with at least one cavity to define a unit dosage of the composition and forming a leak resistant seal enclosing the unit dosage quantity of the composition within the cavity;
(b) subjecting the storage container containing the unit dosages to freezing;
(c) removing at least one of the solid unit dosages from said storage container; and
(d) administering said at least one solid unit dosage to a human.

### Claim 38 (depends on 37)

The method of claim 37 wherein freezing includes subjecting the storage container to a temperature of below 5° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form, said solid unit dosage form suitable for one of oral, rectal or vaginal administration.

### Claim 39 (depends on 38)

The method of claim 38 wherein freezing includes subjecting the storage container to a temperature of below 0° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 40 (depends on 38)

The method of claim 38 wherein freezing includes subjecting the storage container to a temperature in the range of −20° C. to 0° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 41 (depends on 37)

The method of claim 37 wherein unit dosage quantity is in liquid or flowable form at room temperature prior to freezing.

### Claim 42 (depends on 37)

The method of claim 37 wherein the unit dosage quantity is in liquid or flowable form at a temperature in the range of 10° C. to 35° C., prior to freezing.

### Claim 43 (depends on 37)

The method of claim 37 wherein the composition has a freezing point below 0° C.

### Claim 44 (depends on 37)

The method of claim 37 wherein the unit dosage quantity solidifies into a solid unit dosage form upon freezing with a temperature in the range of −20° C. to 5° C.

### Claim 45 (depends on 37)

The method of claim 37 wherein the symptoms and conditions is one or more of bacterial, viral, and fungal infections, the common cold or flu, bronchitis, upper respiratory tract infection, pneumonia, aches, pain, headache, nasal and sinus congestion, sore throat, cough, hoarseness, oral or rectal discomfort and irritation, malaise, fatigue, insomnia, mood disorders, depression, cholesterol level disorders, allergic reactions, stress, sleeplessness, anxiety, digestive disorders, gastrointestinal disorders, kidney disorders, bowel and urinary disorders, dementia, delirium, fever, hypertension, heart and vascular disorders, diabetes and related conditions, inflammation, autoimmune and immunodeficiency disorders, respiratory disorders, and disorders due injury.

### Claim 46

A kit comprising:
(a) a composition comprising at least one active ingredient and a physiologically or pharmaceutically acceptable carrier, said composition having a freezing point of 5° C. or less;
(b) a storage container comprising one or more liquid-impermeable cavities, each cavity configured to receive a unit dosage quantity of the composition; and
(c) a sealing sheet for sealing engagement with the storage container, the sealing sheet adapted to cooperate with at least one cavity to define a unit dosage of the composition and to form a leak resistant seal enclosing the unit dosage quantity of the composition within the cavity; and
(d) an instruction to subject the storage container containing the unit dosages in at least one or more of the cavities to freezing;
wherein the unit dosage quantity solidifies into a solid unit dosage of the composition within each cavity upon freezing, said solid unit dosage form suitable for one of oral, rectal or vaginal administration.

### Claim 47 (depends on 46)

The kit of claim 46 wherein freezing includes subjecting the storage container to a temperature of below 5° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form, said solid unit dosage form suitable for one of oral, rectal or vaginal administration.

### Claim 48 (depends on 46)

The kit of claim 46 wherein freezing includes subjecting the storage container to a temperature of below 0° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 49 (depends on 46)

The kit of claim 46 wherein freezing includes subjecting the storage container to a temperature in the range of −20° C. to 0° C., for a period of time sufficient to freeze the unit dosages into a solid unit dosage form.

### Claim 50 (depends on 46)

The kit of claim 46 wherein the instruction further comprises an instruction to administer the at least one of the solid unit dosages.

### Claim 51

A solid unit dosage for one of oral, vaginal or rectal administration for locally or systemically treating symptoms or conditions of a human in need of such treatment, comprising a unit dosage quantity of a composition, said composition comprising at least one active ingredient and a physiologically or pharmaceutically acceptable carrier, said composition having a freezing point of 5° C. or less; said unit dosage quantity being in liquid or flowable form at room temperature prior to freezing, and said unit dosage quantity solidifying into a solid unit dosage upon freezing,

### Claim 52 (depends on 51)

The solid unit dosage of claim 51 wherein the unit dosage quantity is in liquid or flowable form at a temperature in the range of 10° C. to 35° C. prior to freezing.

### Claim 53 (depends on 51)

The solid unit dosage of claim 51 wherein the unit dosage quantity solidifies into a solid unit dosage form upon freezing at a temperature in the range of −20° C. to 5° C.

### Claim 54 (depends on 51)

The solid unit dosage of claim 51 wherein the unit dosage quantity substantially conforms to the configuration defined by a storage container or a compartment thereof within which the unit dosage quantity is contained when subjected to freezing, thereby providing a configuration for the solid unit dosage.

### Claim 55 (depends on 51)

The solid unit dosage of claim 51 wherein the solid unit dosage is adapted for one of oral, rectal or vaginal administration.

### Claim 56 (depends on 54)

The solid unit dosage of claim 54 wherein the solid unit dosage is in a configuration selected from the group consisting of lozenge, tablet, capsule, ring, star, geometric shapes, suppository, torpedo or candy confectionery.

### Claim 57 (depends on 51)

The solid unit dosage of claim 51 wherein the active ingredient is an herbal, pharmaceutical or nutritional ingredient.

### Claim 58 (depends on 51)

The solid unit dosage of claim 51 wherein the active ingredient is selected from the group consisting of dextromethophan, guaifenesin, lidocaine/sylocalne, phenylephrine, codeine sulfate, benzydamine, aspirin, non-steroidal anti-inflammatory drugs such as arylalkanoic acids, 2-arylpropionic acids, N-arylanthranilic acids, pryrazolidine derivatives, oxicans, COX-2 inhibitors or sulphonanilides, acetominophen, ibuprofen, amoxicillin, garlic, arabinogalactan, St. John's wart, goldenseal, eyebright, licorice, rose hips, chamomile, slippery elm bark, echinacea, ginkgo biloba, red doer, sarsaparilla, uva ursi, aloe vera, black cohosh, green tea, cat's claw, devil's claw, buchu, ginseng, dandelion, raspberry leaf, spearmint, peppermint, comfrey, senna, feverfew, ginger, calendula, dong quai, cranberry, ephedra, hawthorn, juniper, thistle, valerian, elder tree, green coffee bean, green cacao bean, artichoke, birch tree, wild yam, agnus castus, passion flower, saw palmetto and schizandra.

### Claim 59 (depends on 51)

The solid unit dosage of claim 51 wherein the active ingredient includes one of acetaminophen, amoxicillin, ginseng or Echinacea.

### Claim 60 (depends on 7, 35, 36, 51)

The solid unit dosage according to any one of claim 7, 35, 36 or 51 wherein the symptoms and conditions is one or more of bacterial, viral, and fungal infections, the common cold or flu, bronchitis, upper respiratory tract infection, pneumonia, aches, pain, headache, nasal and sinus congestion, sore throat, cough, hoarseness, oral or rectal discomfort and irritation, malaise, fatigue, insomnia, mood disorders, depression, cholesterol level disorders, allergic reactions, stress, sleeplessness, anxiety, digestive disorders, gastrointestinal disorders, kidney disorders, bowel and urinary disorders, dementia, delirium, fever, hypertension, heart and vascular disorders, diabetes and related conditions, inflammation, autoimmune and immunodeficiency disorders, respiratory disorders, and disorders due injury.

### Claim 61 (depends on 60)

The solid unit dosage of claim 60 wherein the solid unit dosage is a throat lozenge.

### Claim 62 (depends on 60)

The solid unit dosage of claim 60 wherein the solid unit dosage is a rectal or vaginal suppository.
